Welcome, Guest
Username: Password: Remember me
  • Page:
  • 1
  • 2

TOPIC: Prof Ed Gane's remarks: implications for Twinvir

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9908

  • Thurl
  • Thurl's Avatar
  • Offline
  • Junior Member
  • Posts: 24
  • Thank you received: 52
  • Karma: 0
The remarks attributed to Prof Ed Gane on NZ radio recently that “there's a lot of concern about drugs coming out of Bangladesh at the moment” may cause some alarm and apprehension to, amongst others, those like me who are using Incepta's Twinvir – which comes from Bangladesh. Prof Gane's alleged remark about “concern about drugs coming out of Bangladesh” does not identify Twinvir by name, and is certainly not limited to Twinvir, but seems wide enough to include Twinvir.

How can anyone using Twinvir set their minds at rest that Prof Gane's remarks are groundless at least as far as Twinvir is concerned? At the moment I can think of only two ways. First, is there currently any reliable evidence that someone – anyone - has actually achieved SVR12 (or failing that SVR4) through the use of Twinvir? (Bearing in mind I am not sure if Twinvir has yet been on the market long enough for the period of 12 weeks treatment plus 12 weeks of post-treatment for a Twinvir-user to get to SVR12.)

Secondly, is there anyone of a scientific background who can confirm as scientifically correct the point attributed to Prof Ed Gane that a chemical may be confirmed as genuine Ledipasvir in a laboratory test but still not be effective as a medicine against the virus because it is not in the necessary “active, crystalline form”?

I tentatively suggest that anyone on this forum using Twinvir, or any other generic covered by Prof Gane's remark, could help each other by sharing information on their post-treatment results - whether that be SVR4 or SVR12, or relapse.
Male Geno 1a F3-4 Tx Naive
Contracted early 1970s Diagnosed 2012
Started 12 wks TWINVIR (Sof/Led) on 15 Nov 2015
Pre-treatment VL 1.8 million
UND at 8 Dec 2015; UND at 12 Jan 2016
Ended 12 wks TWINVIR on 6 Feb 2016
9 Feb 2016 EOT VL test <15 PCR Negative
UND at 3 May 2016 SVR12
The administrator has disabled public write access.
The following user(s) said Thank You: Lynne-Francis-facebook, Tina-Hill-facebook

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9921

Hi Thurl

I finish my 12 week course of Sof/Led on Thursday and will post my 4 week post treatment results once I have them. Apprehensive but hopeful.

Cheers Lynne
Lives in Bendigo, Victoria
No prior treatment Genotype 1b Fibroscan 0 (only showed a bit of a fatty liver) Diagnosed in February 2015 Currently on my last week of treatment taking led/sof Last LFT normal
Insomnia the only side effect
Undetected at 4 weeks
SVR4 - undetected - all bloods good and GP very happy
SVR12 bloods to be done at end of April 2016
SVR12 - undetected!!!
The administrator has disabled public write access.
The following user(s) said Thank You: Thurl

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9930

  • Asif Mostafa
  • Asif Mostafa's Avatar
  • Offline
  • New Member
  • Posts: 3
  • Thank you received: 19
  • Karma: 0
Hello Thurl,

Twinvir was launched on 27th of August. I launched the product. Patients started using this medicine from September earliest. SVR 12 is measured 12 weeks after treatment cessation. So no, there hasn't been sufficient time to measure to SVR12 is any patients. But there are a number of patients who had been undetectable viral load during treatment. You are taking Twinvir. Have you measured your viral load during this time. What is your viral load status? I haven't read the comment of the New Zealand doctor. Can you share the link with me?
Asif Mostafa
M. Pharm (DU), MBA (IBA)
Senior Brand Manager
Incepta Pharmaceuticals Ltd.
40 Shahid Tajuddin Sharani,Tejgaon 1/A, Dhaka-1208
Phone:8891688-703 (Ex. 155)
Fax: +880-2-8891190
Mobile: +88-01713-338492
Available at Viber and whatsapp
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
The administrator has disabled public write access.
The following user(s) said Thank You: Enkel, Thurl

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9931

  • Chapel
  • Chapel's Avatar
  • Offline
  • Premium Member
  • Posts: 122
  • Thank you received: 132
  • Karma: 2
Asif, here is the link and also a link to another relevant post on here with some text

www.radionz.co.nz/national/programmes/ni...tis-c-buyers%27-club

(Prof Gane speaks near the end of the sound file at the bottom of the page)

Also some text here: fixhepc.com/forum/media-news/656-prof-ed...nine-to-noon-nz.html
M, 57, Live in Wellington,NZ.
Genotype 1a diagnosed in 2013.
Treating for the first time since October 31 with Buyers Club Sof/Led. Thanks so much guys. Minimal side effects apart from sore throat at the start..
Viral load 5.4m when treatment started, Undetected at 4 weeks, 8 weeks, End of Treatment and 12-weeks post EOT. Yay!
Last Edit: 6 years 3 months ago by Chapel. Reason: Added url for another post
The administrator has disabled public write access.
The following user(s) said Thank You: Thurl, Asif Mostafa

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9932

  • DrJames
  • DrJames's Avatar
  • Offline
  • Platinum Member
  • Posts: 1980
  • Thank you received: 7261
  • Karma: 111
Twinvir launched on the 27th August 2015, so there are patients past SVR4 but not SVR12. The first SVR12 results will appear in mid March.

My first patients started on it mid November. All were viral load zero within 4 weeks.

Prior to using it we tested Twinvir at the NATA accredited National Measurement Institute. If you search the certification documents for Sofosbuvir and Ledipasvir for the word Twinvir you will see that testing noted. You can find those certification reports here:

fixhepc.com/blog/item/16-testing-provisions-patient-safety.html

We did RVR testing on Twinvir during the period 20-28 November and observed excellent clinical effects with the worst 1 week viral load drop being 1,200,000 -> 636 (F3), the best being 2 million to undetected.

If you read the TGA submission here:

www.tga.gov.au/file/8444/download

You will find it stated that:

Ledipasvir is practically insoluble (<0.1 mg/mL) across the pH range of 3.0-7.5 and is slightly soluble below pH 2.3 (1.1 mg/mL). The partition coefficient (log P) for ledipasvir is 3.8 and the pKa1 is 4.0 and pKa2 is 5.0.

This is why you must have stomach acidity to absorb it - without that it won't dissolve well. Once it is dissolved it's not in a crystalline form and will be absorbed. The normal volume of the stomach fluid is 20 to 100 mL and the pH is acidic (1.5 to 3.5) so I'm actually quite surprised it is not without food (to increase the acidity) but as you will read in the auspar document it still gets absorbed in the presence of food.

If you read Gilead's submission to the European Medicines Agency here:

www.ema.europa.eu/docs/en_GB/document_li...3850/WC500177996.pdf

On page 8 you will find Gilead stating:

Three crystalline forms are known and ledipasvir acetone solvate is the designated commercial form. The first step for finished product manufacture involves the dissolution of ledipasvir in ethanol followed by spray-drying and thus precise control of morphology and particle size is not considered important.

Ledipasvir acetone is what Twinvir uses.

On the topic of crystalline forms most people don't know that Gilead tested crystalline Form-I Sofosbuvir but substituted Form-II in the commercial product. See page 12 here, and note that the AUC data in the commercial product is inferior to what was trailed.....

www.tga.gov.au/file/6066/download

We will be publishing generic SVR results at EASL if our abstract is accepted. The are no nasty surprises in it.
YMMV
Last Edit: 6 years 3 months ago by DrJames.
The administrator has disabled public write access.

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9944

  • Vororo
  • Vororo's Avatar
  • Offline
  • Platinum Member
  • Posts: 334
  • Thank you received: 1047
  • Karma: 15
To have someone like Prof Gane speaking publicly about sourcing and using generics is an extremely strong endorsement of what Dr James is doing. Yes, there is the usual institutional caution - don't forget he is speaking as both individual specialist, but also as a representative of the NZ health service. So it is quite correct that he should voice some reservations about the authenticity of medications that have not been approved by MedSafe.

The only remark that I found difficult to accept was the notion that someone *might* achieve a SVR under generic versions of Sofosbuvir plus Ledipasvir but then in some way be more likely to rebound if they had taken a sub-standard version of Ledipasvir.

This seems to suggest that one can have UND (meaning undetectable because there absolutely no virus to detect), and UND meaning still some virus remaining (but an undetectable amount) which also has some "memory" that the Led taken was sub-standard. This seems to me to be arguing about what might happen with some tiny handful of hypothetically-still-existing virus particles which somehow might "know" what they are allowed to do next...

Last virus particle #1: Shoot, where has everyone gone?

Last virus particle #2: They just got zapped by a sub-standard version of of Ledipasvir. We're the only two left.

Last virus particle #1: It was sub-standard? Ok, let's start replicating again then.

Last virus particle #2. Urghhh.

Last virus particle #1. What was that?

Last virus particle #2. An antibody just ripped my head off. So long...

Last virus particle #1. Oh no, another antibody... Self-destruct in T-5 seconds...

If one gets down to UND during treatment, then surely the Sof+Led combo has done the job regardless of their crystal forms, and the usual SVR projections with the usual margins of error should apply?
Diagnosed Jan 2015: GT3, A0+F0/F1. Fatigue + Brain-Fog.
Started Sof+Dac from fixHepC 10-Nov-2015. NO sides.
Pre-Tx: AST 82, ALT 133, Viral Load 1 900 000.
Week4: AST 47, ALT 58. VL < 15 (unquantifiable).
Week12 (EOT): AST 30, ALT 26, VL UND
Week16 (EOT+4): AST 32, ALT 28, GGT 24, VL UND
Week28 (EOT+16): AST 26, ALT 22, GGT 24, VL UND
Ever grateful to Dr James.

Relapsed somewhere after all that... Bummer!

Jan 2018: VL 63 000 (still GT3).
The administrator has disabled public write access.
The following user(s) said Thank You: Chapel, Thurl, Lynne-Francis-facebook, Tina-Hill-facebook, Jimmy6429, Hazel

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9950

  • Chapel
  • Chapel's Avatar
  • Offline
  • Premium Member
  • Posts: 122
  • Thank you received: 132
  • Karma: 2
Vororo, thanks so much for your comment, the chemistry is beyond my education. That scenario of generic Ledipasvir leading to relapses is a very scary one and I would love for it to be a fantasy/scare mongering. My specialist told me reaching UND would be a big test of the generic meds. Well I crossed that bridge at 4 weeks, now we have NZ's most prominent specialist suggesting it might unravel. What about the theory that taking Sofosbuvir alone might lead to UND, which he seems to suggest?
M, 57, Live in Wellington,NZ.
Genotype 1a diagnosed in 2013.
Treating for the first time since October 31 with Buyers Club Sof/Led. Thanks so much guys. Minimal side effects apart from sore throat at the start..
Viral load 5.4m when treatment started, Undetected at 4 weeks, 8 weeks, End of Treatment and 12-weeks post EOT. Yay!
The administrator has disabled public write access.
The following user(s) said Thank You: Thurl, Lynne-Francis-facebook

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9952

  • Thurl
  • Thurl's Avatar
  • Offline
  • Junior Member
  • Posts: 24
  • Thank you received: 52
  • Karma: 0
Thanks Lynne. It seems you are not much further ahead in treatment than I am. I will finish my 12-week course of Twinvir on Saturday. I will also post my results EOT. The best way to rebut Prof Gane is to show that that people using generics containing unlicensed Chinese-made ledipasvir (which seems to be the generic drug Prof Gane is most concerned about) can achieve SVR rates comparable to the equivalent branded medicines. People on the branded medicines, as well as people on generics (licensed and unlicensed), can relapse and no-one is expecting the generics to actually do better than the equivalent brand medicines. So stories of occasional relapse on generics do not call into question the efficacy of generics any more than occasional relapses on brands call into question the efficacy of the brands. What matters is to establish an overall picture of SVR rates for generics, particularly the unlicensed generics, which is comparable to the brand versions; that can only emerge if generic-users share their post-treatment results, whether as part of a formal study, as I understand Dr Freeman's to be, or not.

Asif – thanks for your post. My on-treatment results have been fine. Pre-treatment my VL was 1.8 million with ALT 176 and AST 106 . By week 4 of treatment my VL was undetected and my ALT and AST were both back in the normal range. At week 8 of treatment I remained VL undetected. However, according to Prof Gane little reassurance can be obtained from on-treatment results. What matters is the post-treatment results. This is because where ledipasvir is combined with sofosbuvir, which it usually is, Prof Gane says the sofosbuvir may be effective while the ledipasvir is not. In this situation, according to Prof Gane, the sofosbuvir alone can maintain viral-suppression as long as treatment is maintained but when treatment is finished if the ledipasvir component of the medicine was ineffective the virus will then spring back causing relapse.

Chapel - thank you for posting the link. I agree with you that Prof Gane's remarks seem to suggest that one way to respond to relapse - should it happen - is to go on permanent, lifelong sofosbuvir treatment, which alone should be enough to maintain viral suppression, if not cure - a bit like I understand that HIV patients take permanent, lifelong viral suppression medication. Is this correct? Could this be a way of dealing with relapse?
Male Geno 1a F3-4 Tx Naive
Contracted early 1970s Diagnosed 2012
Started 12 wks TWINVIR (Sof/Led) on 15 Nov 2015
Pre-treatment VL 1.8 million
UND at 8 Dec 2015; UND at 12 Jan 2016
Ended 12 wks TWINVIR on 6 Feb 2016
9 Feb 2016 EOT VL test <15 PCR Negative
UND at 3 May 2016 SVR12
The administrator has disabled public write access.
The following user(s) said Thank You: dointime, mgalbrai, Jimmy6429

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9953

  • kenbasman
  • kenbasman's Avatar
  • Offline
  • Elite Member
  • Posts: 164
  • Thank you received: 241
  • Karma: 0
It sounds like scare tactics to me. They haven't tested the meds and are commenting on the possibility of them not being up to snuff. If they haven't tested the meds it doesn't seem to be very scientific on their part. You'd figure a knowledgable expert would do some clinical research before speaking about possible problems. Twinvir has been tested here and passed. Lesovir-C is made by Beximco and they are a drug company with FDA approval. Hmmmm. I guess we will all have to wait and see.
HCV 35 yrs G1a F3 Tx naive
started Lesovir-C 15/12/2015
pre tx: VL 5,250,000 ALT 374 AST 208
FIBROSCORE 10.4

4 weeks tx ALT 29/ AST 33. VL < 12 UI/mL
8 weeks tx ALT 29/ AST 34. VL UND
4 weeks after tx UND. SVR4. ALT 24/AST 18
The administrator has disabled public write access.
The following user(s) said Thank You: LondonGirl, mgalbrai, Hazel

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9954

  • mgalbrai
  • mgalbrai's Avatar
  • Offline
  • Moderator
  • Posts: 1327
  • Thank you received: 2695
  • Karma: 26
I once asked Rachel at Mesochem if she sold simeprevir and if so, what was the price. Her response: "We sell simeprevir, but not simeprevir sodium". Turns out plain old simeprevir can't be absorbed by the body. It has to be processed further into "simeprevir sodium".
I think the Mesochem ledipasvir is perfect. So is the dac. Some people have far different reactions to meds than others. I took generics for four weeks, then switched to Harvoni-no difference. The generics nailed the virus in four weeks-just like many if you are seeing or about to see. I can't be used as a reference because I finished up with Harvoni. Not because of worries about generic quality, but because I had fought my ass off for two years to get them
Why would a company like Mesochem go to the trouble of making something so complicated and not make it right?
I think Gane is a "company man" giving us the "company line". They can't attack our system, so they attack the medicine. In a very few months, they will lose that opportunity when all the SVR 12 tests start rolling in. This is Gilead's Battle of the Bulge- their primary weapons are fear and disinformation.
Its a long way from Arkansas to NZ, but fear-mongering seems to work wherever its practiced.
M
This email address is being protected from spambots. You need JavaScript enabled to view it.
forums.delphiforums.com/generichcvtx

G 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 24
The administrator has disabled public write access.
The following user(s) said Thank You: Lynne-Francis-facebook

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9955

  • Vororo
  • Vororo's Avatar
  • Offline
  • Platinum Member
  • Posts: 334
  • Thank you received: 1047
  • Karma: 15
Hi Chapel,

I don't remember what prof Gane said about Sofosbuvir alone and rebound after SVR. I don't have time to listen again to the broadcast. But here is an earlier post from Dr James on log kill and treatment failure mechanisms:

fixhepc.com/forum/resistance/164-resista...lure-mechanisms.html

The key is to zap the virus as quickly as possible with a high log kill in the first weeks. Then even if "UND" might mean a few undetectable stragglers remain, a few more weeks of treatment would guarantee that they also eventually get whacked. I imagine that if someone gets UND on Sof alone, then there would only be a risk of rebound if the UND appeared right at the end of the treatment. So this is why a dual DAA combo is always recommended, and why triple or even quad-combos (3-week treatment) is the way of the future:

fixhepc.com/forum/media-news/512-raymond...g-generics.html#6378

If 3-weeks of quad-DAA really is enough, it seems to me that this must mean reaching UND in just a few days!

So if you or Lynn are at UND after 4 weeks on dual-DAAs, it seems a pretty safe bet that you can now relax and enjoy the show...
Diagnosed Jan 2015: GT3, A0+F0/F1. Fatigue + Brain-Fog.
Started Sof+Dac from fixHepC 10-Nov-2015. NO sides.
Pre-Tx: AST 82, ALT 133, Viral Load 1 900 000.
Week4: AST 47, ALT 58. VL < 15 (unquantifiable).
Week12 (EOT): AST 30, ALT 26, VL UND
Week16 (EOT+4): AST 32, ALT 28, GGT 24, VL UND
Week28 (EOT+16): AST 26, ALT 22, GGT 24, VL UND
Ever grateful to Dr James.

Relapsed somewhere after all that... Bummer!

Jan 2018: VL 63 000 (still GT3).
Last Edit: 6 years 3 months ago by Vororo. Reason: fixed triple/quad
The administrator has disabled public write access.
The following user(s) said Thank You: mgalbrai, Lynne-Francis-facebook

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9957

  • Sirchinenge
  • Sirchinenge's Avatar
  • Offline
  • Moderator
  • What a difference a year makes:)
  • Posts: 269
  • Thank you received: 366
  • Karma: 3
The Stats may be slightly behind on Generics everything I have read/seen about these drugs suggests if you
reach Undetected by week/2/4/6/8/10/12 you have a 98% chance of being SVR at 12 weeks post treatment.

Look at the results thus far, most if not all of those on Twinvir are UD by week 12 at the latest, if Sob was
the only ingredient working we would see about 30% not reaching UD at all throughout the 12 weeks.

So, the suggestion that Sob alone is keeping the virus UD during treatment leading to failure post treatment
is not within any research I have read at all.

Thurl, my understanding of those who fail treatment is you re-treat them I have never heard of anyone yet having to do
life long suppression treatment I guess for the small % who fail its an option.
Sob/Dac from Oct 29 2015
Geno 1b
Fiberscan 9.9 Pre treatment
Fiberscan 7.4 week 10
VL 1.3 million pre treatment
Week 2.5 VL 96
Week 5.5 VL 17
Week 10 VL UD
SVR 3 UD
SVR 16 UD
Cured:
All liver functions in normal ranges.
Last Edit: 6 years 3 months ago by Sirchinenge.
The administrator has disabled public write access.

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9962

  • Gaj
  • Gaj's Avatar
  • Offline
  • Moderator
  • Optimist :-)
  • Posts: 1436
  • Thank you received: 3082
  • Karma: 32
Prof Gane's fields of expertise are hepatology and virology not API molecular chemistry and manufacturing. He will be receiving advice about those aspects as do all experts about related but non core areas. As he is an intelligent man with some knowledge that advice will need to be plausible for him to heed it and issue a warning. But plausible does not equal correct and may be applicable in some instances but not others.

The comment about needing sophisticated facilities to manufacture Ledipasvir sounds about right. However, mentioning that in the same interview as expressing concerns about some Chinese manufactured drugs does not mean that Mesochem is incapable of producing quality Ledipasvir.
G3a since '78 - Dx '12 - F4 (2xHCC)
24wk Tx - PEG/Riba/Dac 2013 relapsed
24wk Tx - Generic Sof/Dac/Riba 2015/16 relapsed
16wk Tx - 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof
SVR7 - 22/06/17 UND
SRV12 - 27/07/17 UND
SVR24 - 26/10/17 UND
:cheer: :cheer: :cheer:
Last Edit: 6 years 3 months ago by Gaj.
The administrator has disabled public write access.
The following user(s) said Thank You: mgalbrai, Lynne-Francis-facebook, Tina-Hill-facebook, Hazel

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9964

  • mgalbrai
  • mgalbrai's Avatar
  • Offline
  • Moderator
  • Posts: 1327
  • Thank you received: 2695
  • Karma: 26
I understand little about chemistry and chemical makeup. There surely must be a way to take a sample of Mesochem ledipasvir and determine, beyond any doubt, its exact properties. I understand it has been analyzed many, many times, but Gane obviously is sowing doubt about the results.
REDEMPTION is testing its efficacy.
M
This email address is being protected from spambots. You need JavaScript enabled to view it.
forums.delphiforums.com/generichcvtx

G 1a F-1
Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil
11/17/15 4 wk lab ALT 17 AST 16 <15
11/18/15 Started Harvoni
12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND
1/14/16 Fin. Tx
7/07/16 UND SVR 24
The administrator has disabled public write access.

Prof Ed Gane's remarks: implications for Twinvir 6 years 3 months ago #9968

  • Wayne
  • Wayne's Avatar
  • Offline
  • Junior Member
  • Posts: 38
  • Thank you received: 61
  • Karma: -1
As Doctor James said by nature Doctors are conservative for our good do you think Dr James would write a script for something he didn't have confidence in or the Compounding Pharmacies which are registered Australian Businesses would distribute meds they are unsure about They are all tested look at the massive HCV viral destruction going on here these meds are the real deal Professor Gane and rightly so is just exercising caution but also appears encouraged by FixHep C result. my take anyway. :+1:
Genotype 1b 42 years.
2007 48 Weeks Interferon + Ribavirin Relapsed.
2015 6 Weeks same as above + Sempivir Too many sides stopped.
7/11/15 started Sof / Dac + Riba 24 Weeks. Kingswood Pharmacy.
VL Before tx 3 million.
1st bloods 8 weeks undetected
.
The administrator has disabled public write access.
The following user(s) said Thank You: mgalbrai, Gaj, Lynne-Francis-facebook, Tina-Hill-facebook, Hazel
  • Page:
  • 1
  • 2
Time to create page: 0.099 seconds

Copyright © 2015-2020 FixHepC

Back to Top